CRDF at a glance
Cardiff Oncology, Inc. (CRDF, SEC CIK 1213037) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as July 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cardiff Oncology, Inc. (CRDF) reported revenue of $593,000 (down 13.2% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$0.69.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Cardiff Oncology, Inc. (CRDF) shares worth $10.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by PACE GARY W on July 14, 2026 of 687,285 shares at $1.46 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $593K
- −13.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $10.6M · −5 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
- Carried-forward risks not specified in provided section
Management Discussion & Analysis
- Quarterly revenue $0.2M vs $0.1M YoY
- R&D expense $5.0M vs $8.2M YoY, SG&A $4.4M vs $3.9M
- Best program: 30 mg onvansertib plus FOLFIRI/bev, ORR 72.2% vs 42.1% SoC
- Cash, equivalents and short-term investments $33.8M at September 30, 2026, operating cash use $33.9M
- Funding projected through Q3 2027, substantial going-concern doubt and additional capital required
AI summary of the CRDF 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 business update and financial results announced for quarter ended September 30, 2026
- Full operating and financial details contained in Exhibit 99.1, Cardiff Oncology’s accompanying press release
Item EX-99.1: Item EX-99.1
- Phase 2 efficacy signal strengthening: median PFS not reached at 30 mg onvansertib plus FOLFIRI/bev versus approximately 11 months for combined SoC arms
- All remaining patients in the proposed Phase 3 regimen exceeded 21 months on treatment, with longest duration over 29 months
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Medical Officer Roger Sidhu departed October 22, 2026 through a mutually agreed transition
- Leila Alland appointed interim Chief Medical Officer effective October 23, 2026
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Authorized common shares increased to 300,000,000, expanding potential equity issuance capacity
- Effective October 22, 2026 upon Delaware filing
Item EX-99.1: Item EX-99.1
- Leila Alland, MD appointed interim Chief Medical Officer, replacing Roger Sidhu
- Leadership change arrives before planned Phase 3 launch in first quarter 2027
Item 7.01: Regulation FD Disclosure
- Dr. Sidhu resigned as Chief Medical Officer, creating a senior clinical leadership transition
- Dr. Alland appointed interim Chief Medical Officer, providing temporary oversight of clinical development
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders approved expanding authorized capital from 170 million to 320 million shares
- Common-stock authorization increased from 150 million to 300 million shares
AI summaries of CRDF 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRDF
Don't miss the next CRDF filing
- Alerts as it files. A push when CRDF files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRDF, by share count.
- Ask anything. An AI agent that reads every CRDF filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| PACE GARY W | Buy | Jul 14, 2026 | 687,285 | $1.46 |
| Mohindru Mani | Buy | Jul 14, 2026 | 34,364 | - |
| Mohindru Mani | Buy | Jul 14, 2026 | 34,364 | $1.46 |
| PACE GARY W | Buy | Jul 14, 2026 | 687,285 | - |
| PACE GARY W | Buy | Jun 18, 2026 | 30,000 | $1.22 |
| Mohindru Mani | Buy | Jun 18, 2026 | 24,703 | $1.21 |
| TANNENBAUM RENEE P | A | Jun 11, 2026 | 40,565 | - |
| Armitage James O | A | Jun 11, 2026 | 40,565 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $683K | $593K |
| Operating Income | - | -$48.7M | -$49.0M |
| Net Income | -$41.4M | -$45.4M | -$45.9M |
| Op. Margin | - | -7123.1% | -8256.3% |
| Net Margin | - | -6651.7% | -7732.0% |
| Balance Sheet | |||
| Total Assets | - | $97.2M | $61.9M |
| Equity | $69.7M | $82.9M | $45.4M |
| ROE | -59.4% | -54.8% | -101.0% |
| Per Share | |||
| EPS | $-0.93 | $-0.95 | $-0.69 |
| Cash Flow | |||
| Operating CF | - | -$37.7M | -$37.9M |
| CapEx | $582K | $80K | $44K |
Source: XBRL data in Cardiff Oncology, Inc. (CRDF)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CRDF share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $10.6M |
| Q2 2026 | 23 | $11.9M |
| Q1 2026 | 26 | $22.4M |
| Q4 2025 | 22 | $40.6M |
| Q3 2025 | 24 | $28.3M |
| Q2 2025 | 24 | $48.9M |
| Q1 2025 | 21 | $31.7M |
| Q4 2024 | 19 | $33.5M |
- Two Sigma Investments+274.2K (+575%)
- Renaissance Technologies LLC+37.9K (+272%)
- Goldman Sachs Group+34.3K (+28%)
- AQR Capital Management−293.0K (-85%)
- Morgan Stanley−65.5K (-27%)
- BlackRock−37.0K (-4%)
- Vanguard Capital Management LLC−27.7K (-1%)
- Millennium Management−18.1K (-13%)
- Vanguard Portfolio Management LLC−72.1K
- Bank of America Corp−12.2K
- FMR LLC (Fidelity)−9.8K
- PNC Financial Services−2.2K
- Citigroup−501
Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRDF filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | May 29, 2026 | - | Analysis | |
| 8-K | May 19, 2026 | - | Analysis | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 28, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CRDF SEC filings: frequently asked questions
Which institutions hold CRDF stock?
As of September 30, 2026, the largest Cardiff Oncology, Inc. (CRDF) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($3.5 million), Pfizer Inc ($3.0 million), BlackRock ($1.1 million), Franklin Resources ($1.0 million), State Street Corp ($392,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRDF's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cardiff Oncology, Inc. (CRDF) reported revenue of $593,000 (down 13.2% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$0.69. The figures come from the XBRL data in the 10-K.
What did CRDF report in its latest 8-K?
Cardiff Oncology, Inc. (CRDF) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 business update and financial results announced for quarter ended September 30, 2026.
What are the latest CRDF SEC filings?
Cardiff Oncology, Inc. (CRDF) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on July 16, 2026.
What is CRDF's SEC CIK number?
Cardiff Oncology, Inc. (CRDF)'s SEC Central Index Key (CIK) is 1213037. EDGAR lists every CRDF filing under that number.
Ask anything about CRDF
The research agent reads CRDF's filings, financials, insider trades and 13F holders, then answers with sources.